Does Humana Cover Armour Thyroid?

Humana Formulary Placement for Armour Thyroid

Armour Thyroid appears on most Humana commercial formularies as a Tier 3 (non-preferred brand) medication, which means higher out-of-pocket costs compared to Tier 1 generics like levothyroxine. Tier 3 copays on Humana plans typically range from $40 to $80 per fill.

Humana publishes its formulary lists by plan year and region, and placement can shift during the annual formulary review cycle. Members should verify their specific plan's drug list through Humana's online formulary search tool or by calling the number on the back of their member ID card. The American Thyroid Association (ATA) 2014 guidelines recognize desiccated thyroid as a treatment option for hypothyroidism, which supports medical-necessity arguments when a plan questions coverage. Armour Thyroid's FDA-approved labeling lists hypothyroidism and pituitary TSH suppression as its approved indications.

Humana Medicare Advantage plans follow a separate formulary structure governed partly by CMS formulary guidelines. Some MA plans in certain regions exclude brand-name desiccated thyroid products altogether, directing members to levothyroxine or generic liothyronine instead. If your MA plan excludes Armour Thyroid, you can request a formulary exception (covered in the appeal section below).

Prior-Authorization Criteria on Humana Plans

Many Humana plans require prior authorization before dispensing Armour Thyroid. The typical PA criteria include a confirmed hypothyroidism diagnosis, a recent TSH level showing clinical need, and documentation that the prescriber has considered levothyroxine monotherapy as first-line treatment per ATA recommendations.

A prescriber submitting a PA request to Humana should include the member's TSH and free T4 values from the previous 90 days, the specific Armour Thyroid dose being prescribed, and the clinical rationale for choosing desiccated thyroid over synthetic T4. Humana's standard PA turnaround is 72 hours for non-urgent requests and 24 hours for urgent requests, consistent with CMS-mandated timelines for Medicare Advantage and state insurance regulations for commercial plans.

The most common reason for PA denial is insufficient documentation of levothyroxine failure or intolerance. "Failure" in Humana's criteria usually means persistent symptoms despite a TSH in the reference range on adequate levothyroxine dosing for at least 6 to 8 weeks. Jonklaas et al. (2014) reviewed the evidence behind thyroid hormone replacement and noted that a subset of hypothyroid patients report residual symptoms on levothyroxine alone, a finding that supports step-therapy exceptions when properly documented.

Step-Therapy Requirements: The Levothyroxine-First Rule

Humana's step-therapy protocol for Armour Thyroid reflects a broader insurance-industry pattern. Plans require a trial of levothyroxine (typically 6 to 12 weeks at a therapeutic dose) before approving desiccated thyroid. This approach is rooted in cost management and in ATA guideline recommendations that position levothyroxine as the standard first-line treatment.

To satisfy the step-therapy requirement, the prescribing clinician needs to document the levothyroxine dose tried, duration of the trial, lab results during treatment, and the specific symptoms that persisted. Vague statements like "patient prefers natural thyroid" will not clear the step-therapy gate. Instead, focus the documentation on objective findings and measurable symptom burden.

Hoang et al. (2013) conducted a randomized crossover trial comparing desiccated thyroid extract (DTE) to levothyroxine in 70 hypothyroid patients. Participants lost an average of 3 lbs more on DTE than on levothyroxine over 16 weeks, and 48.6% preferred DTE at study end. That trial did not find a statistically significant difference in cognitive function or quality-of-life scores between the two treatments, but the weight-loss difference and patient preference data can support a step-therapy override request when paired with documented levothyroxine failure.

Some Humana plans grant an automatic step-therapy exception if the member's pharmacy claims history already shows a levothyroxine fill within the past 12 months. Ask the pharmacist to run a claims check before the prescriber submits a manual override.

Humana Medicare Advantage: Regional Variations

Coverage under Humana Medicare Advantage deserves its own discussion because MA formularies differ from commercial formularies in several ways. CMS requires all Part D formularies to cover at least two drugs in each USP therapeutic category, but thyroid hormones are well-served by levothyroxine and liothyronine generics, so plans can technically exclude brand desiccated thyroid without violating CMS rules.

In practice, regional Humana MA-PD plans show a patchwork of coverage decisions. Some Humana Gold Plus plans in the Southeast include Armour Thyroid on Tier 3 with a $47 copay, while certain HMO-based MA plans in the Midwest exclude it entirely. A 2017 analysis of Medicare Part D formulary restrictions found that thyroid-category drugs face fewer utilization-management barriers than specialty medications, but brand products still carry higher rejection rates than generics.

Members enrolled in Humana MA plans that exclude Armour Thyroid can file a formulary exception request. The prescriber must submit a letter of medical necessity explaining why levothyroxine and liothyronine (the formulary alternatives) are not clinically appropriate for the individual patient. CMS requires Humana to respond to exception requests within 72 hours for standard requests and 24 hours for expedited requests.

How to Appeal a Humana Denial of Armour Thyroid

A denial from Humana follows a structured appeal pathway. The process has three stages for commercial plans and up to five stages for Medicare Advantage members.

Commercial plan appeals. File an internal appeal within 180 days of the denial. Include updated lab work (TSH, free T4, free T3), a letter of medical necessity from the prescriber, and documentation of the failed levothyroxine trial. Humana must issue a decision within 30 calendar days for pre-service appeals. If denied again, request an external review through your state's independent review organization. The ATA's 2014 clinical practice guidelines provide a clinician-friendly reference to cite in the appeal letter, specifically the guideline's acknowledgment that combination T4/T3 therapy or desiccated thyroid may be considered for patients who do not respond adequately to levothyroxine alone.

Medicare Advantage appeals. The MA appeal pathway adds layers. After Humana's internal denial (Level 1 reconsideration), you can escalate to Level 2 (Independent Review Entity), then Level 3 (Office of Medicare Hearings and Appeals), and beyond. Most cases resolve by Level 2. The Medicare Prescription Drug Benefit Manual outlines each step and the associated deadlines.

Strong appeal letters share a common structure. They open with the diagnosis (ICD-10 code E03.9 for unspecified hypothyroidism), list the failed alternatives with dates and doses, present supporting lab values, and cite published evidence. Including the Hoang et al. (2013) trial data showing patient preference for DTE and the modest weight-loss advantage adds clinical weight to the request.

Cost Comparison: Covered vs. Cash-Pay vs. Alternatives

Understanding the full cost picture helps if Humana denies coverage and the appeal process stalls. Armour Thyroid's manufacturer list price runs approximately $180 per month for a 30-tablet supply of 60 mg tablets. With Tier 3 Humana coverage, most members pay $40 to $80 out of pocket per fill.

If coverage is denied, cash-pay pricing at independent pharmacies averages $85 per month when using a pharmacy discount card. That figure can drop to $60 to $70 at certain warehouse pharmacies. NP Thyroid, another brand of desiccated thyroid extract, sometimes costs $10 to $20 less per month than Armour Thyroid at cash-pay prices and may have different formulary placement on Humana plans.

Levothyroxine, the Tier 1 generic alternative, costs $4 to $15 per month at most pharmacies. Liothyronine (synthetic T3) generics run $10 to $30 per month. Some clinicians prescribe a levothyroxine-plus-liothyronine combination as a formulary-friendly approximation of desiccated thyroid's T4/T3 ratio, though the ATA guidelines note this approach lacks strong randomized-trial support.

A 2020 survey of hypothyroid patients found that 30.9% of respondents had switched thyroid medications at least once due to insurance-related barriers, and 12.1% reported stopping treatment temporarily because of cost. These numbers highlight why working through the appeal process or identifying an affordable alternative matters for ongoing thyroid management.

Using Manufacturer Savings Cards with Humana

AbbVie (Armour Thyroid's manufacturer) has periodically offered savings cards that reduce the copay for commercially insured patients. These cards typically cannot be applied to Medicare Advantage, Medicaid, or other federally funded insurance programs due to the federal Anti-Kickback Statute.

For Humana commercial members, a manufacturer savings card can reduce the Tier 3 copay by $20 to $50 per fill, depending on the card's terms. The savings card does not count toward the plan's deductible or out-of-pocket maximum. Confirm the card's current availability directly with AbbVie's patient-support line, as savings-card programs change annually.

Patients enrolled in Humana MA plans who face a coverage gap (the Part D "donut hole") may benefit from manufacturer discounts through the Coverage Gap Discount Program, which requires brand manufacturers to offer a 70% discount on brand drugs during the gap phase. Armour Thyroid qualifies for this discount because it is a brand-name product listed in the FDA's Orange Book. After Bipartisan Budget Act of 2018 changes accelerated gap closure, most Part D members now pay 25% coinsurance in the coverage gap, with the manufacturer discount and plan contribution covering the rest.

Armour Thyroid for Weight Loss: Why Humana Will Deny It

Humana will not authorize Armour Thyroid for weight loss in the absence of a hypothyroidism diagnosis. This is consistent across commercial and MA plans. The ATA and Endocrine Society are explicit that thyroid hormone should not be used for weight management in euthyroid patients because of cardiovascular and bone-density risks.

Prescribing thyroid hormone to patients with normal thyroid function accelerates bone turnover. A meta-analysis of subclinical hyperthyroidism (which mirrors the hormonal profile created by exogenous thyroid hormone in euthyroid individuals) found a 1.27 hazard ratio for hip fracture and a 1.68 hazard ratio for atrial fibrillation. These risks explain why payers uniformly restrict thyroid-hormone coverage to diagnosed thyroid disease.

If a patient has both hypothyroidism and obesity, the prescriber should code the claim under the hypothyroidism indication (E03.9 or the specific subcategory) and avoid mentioning weight loss as the treatment goal in the PA documentation. The Hoang et al. trial's finding that DTE produced modest weight reduction compared to levothyroxine occurred in confirmed hypothyroid patients, not in euthyroid individuals seeking weight loss.

Switching from Levothyroxine to Armour Thyroid on Humana

When Humana approves the switch, dosing conversion requires careful attention. The general guideline is that 60 mg (1 grain) of Armour Thyroid provides approximately 38 mcg of T4 and 9 mcg of T3. This is roughly equivalent to 100 mcg of levothyroxine in total thyroid-hormone activity, though the T3 component makes the comparison imperfect.

Clinicians should recheck TSH and free T4 six to eight weeks after the switch, consistent with ATA monitoring recommendations. Because Armour Thyroid contains T3, which has a shorter half-life than T4, some patients notice symptom fluctuations between doses. Splitting the daily dose into a morning and early-afternoon administration can smooth out T3 levels, though this approach is based on clinical experience rather than randomized trial evidence.

Humana's PA approval for Armour Thyroid is typically valid for 12 months. The prescriber must submit a renewal PA before the authorization expires. Keep lab work current (within 90 days of the renewal date) to avoid delays in reauthorization.